ABT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Abbott Laboratories (ABT) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has promising growth prospects in the cancer screening market following its acquisition of Exact Sciences, the current technical indicators, financial performance, and analyst sentiment suggest a cautious approach. The stock is trading below key moving averages, and recent financial results show significant declines in net income and EPS. Analysts have lowered price targets, and the short-term outlook remains weak due to challenges in the Nutrition and Diagnostics segments. It is better to wait for clearer signs of recovery or stronger growth momentum before making a significant investment.
The technical indicators suggest a bearish trend. The MACD is below 0 and negatively contracting, the RSI is neutral at 28.412, and the stock is trading below its 5-day, 20-day, and 200-day moving averages. Key support levels are at 103.418 and 101.188, while resistance levels are at 107.028 and 110.638.
Abbott's acquisition of Exact Sciences positions the company in the $60 billion U.S. cancer screening market, which could drive long-term growth. Gross margin improved YoY, indicating better operational efficiency.
Analysts have lowered price targets due to ongoing challenges in the Nutrition and Diagnostics segments. Technical indicators and trading trends are bearish, with no significant hedge fund or insider activity.
In Q4 2025, revenue increased by 4.42% YoY to $11.46 billion. However, net income dropped by 80.76% YoY to $1.776 billion, and EPS fell by 80.72% YoY to $1.02. Gross margin improved to 53.44%, up 4.91% YoY.
Analysts maintain a generally positive long-term outlook but have lowered price targets due to short-term challenges. Recent ratings include Buy and Overweight ratings with price targets ranging from $120 to $142, reflecting cautious optimism.
